[1] COVID-19 Dashboard [https://coronavirus.jhu.edu/map.html]
[2] COVID-19 vaccine tracker and landscape [https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines]
[3] Ramasamy MN, Minassian AM, Ewer KJ, et al. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. Lancet,2021, 396:1979-1993.
[4] Han B, Song Y, Li C, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial. Lancet Infect Dis, 2021, 21:1645-1653.
[5] Wang FS, Fan JG, Zhang Z, et al. The global burden of liver disease: the major impact of China. Hepatology, 2014, 60:2099-2108.
[6] Qi X, Liu Y, Wang J, et al.Clinical course and risk factors for mortality of COVID-19 patients with pre-existing cirrhosis: a multicentre cohort study. Gut,2021, 70:433-436.
[7] Goes LR, Siqueira JD, Garrido MM, et al.New infections by SARS-CoV-2 variants of concern after natural infections and post-vaccination in Rio de Janeiro, Brazil. Infect Genet Evol, 2021, 94:104998.
[8] Zhang C, Shi L, Wang FS: Liver injury in COVID-19: management and challenges. Lancet Gastroenterol Hepatol,2020, 5:428-430.
[9] McGrowder DA, Miller F, Anderson Cross M, et al. Abnormal Liver Biochemistry Tests and Acute Liver Injury in COVID-19 Patients: Current Evidence and Potential Pathogenesis. Diseases,2021,9:50.
[10] Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA,2020, 323:1061-1069.
[11] Sharma A, Patnaik I, Kumar A, et al.COVID-19 Vaccines in Patients With Chronic Liver Disease. J Clin Exp Hepatol, 2021, 11:720-726.
[12] Guan WJ, Ni ZY, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med, 2020, 382:1708-1720.
[13] Liu H, He X, Wang Y, et al. Management of COVID-19 in patients after liver transplantation: Beijing working party for liver transplantation. Hepatol Int, 2020, 14:432-436.
[14] Qin J, Wang H, Qin X, et al. Perioperative Presentation of COVID-19 Disease in a Liver Transplant Recipient. Hepatology, 2020, 72:1491-1493.
[15] Dale M, Sogawa H, Seyedsaadat SM, et al.Successful Management of COVID-19 Infection in 2 Early Post-Liver Transplant Recipients. Transplant Proc, 2021, 53:1175-1179.
[16] Wang J, Hou Z, Liu J, et al. Safety and immunogenicity of COVID-19 vaccination in patients with non-alcoholic fatty liver disease (CHESS2101): A multicenter study. J Hepatol, 2021, 75:439-441.
[17] Xiang T, Liang B, Wang H, et al.Safety and immunogenicity of a SARS-CoV-2 inactivated vaccine in patients with chronic hepatitis B virus infection. Cell Mol Immunol, 2021,18:2679-2681.
[18] He T, Zhou Y, Xu P, et al. Safety and antibody response to inactivated COVID-19 vaccine in patients with chronic hepatitis B virus infection. Liver Int, 2022, 10.1111
[19] Thuluvath PJ, Robarts P, Chauhan M.Analysis of antibody responses after COVID-19 vaccination in liver transplant recipients and those with chronic liver diseases. J Hepatol, 2021, 75:1434-1439.
[20] Ai J, Wang J, Liu D, et al. Safety and immunogenicity of SARS-CoV-2 vaccines in patients with chronic liver diseases (CHESS-NMCID 2101): A multicenter study. Clin Gastroenterol Hepatol, 2021,S1542-3565:01346-X.
[21] Limited HHMG: Antibody Response to COVID-19 Vaccines in Liver Disease Patients. 2021.
[22] Limited HHMG: A Study to Evaluate Vaccines Against COVID-19 in the Real World. 2021.
[23] Institute of Liver and Biliary Sciences I: Safety and Efficacy of a Non-replicating ChAdOx1 Vector Vaccine AZD1222 (COVISHIELD), for Prevention of COVID-19 in Patients With Liver Cirrhosis. 2021.
[24] Province HSIoG: Effectiveness and Safety of the COVID-19 Vaccination for Patients With Liver Disease (CHESS2101). 2021.
[25] Hospital D: Vaccine Response to COVID-19 Vaccines in Patients Using Immunosuppressive Medication (Nor-vaC). 2021.
[26] University TSAHoCM: Safety and Immune Response of COVID-19 Vaccination in Patients With Chronic Liver Diseases (SIMPLE). 2021.
[27] Hospital B: COVID-19 Vaccines in Patients With Chronic Liver Disease. 2021.
[28] Research PIoMEa: Evaluation of Long Haul COVID-19 and Vaccine Immunogenicity in Patients With Liver Disease (EvaLongCovid). 2021.
[29] Cornberg M, Buti M, Eberhardt CS, et al. EASL position paper on the use of COVID-19 vaccines in patients with chronic liver diseases, hepatobiliary cancer and liver transplant recipients. J Hepatol, 2021, 74:944-951.
[30] 国家卫生健康委员会: 新冠病毒疫苗接种技术指南(第一版).传染病信息 2021,34:97-98.
[31] 中华医学会感染病学分会, 中华医学会风湿病学分会,特殊人群(慢性肝病、结核病和风湿免疫病患者)新型冠状病毒疫苗接种专家建议. 中华传染病杂志,2021, 39:398-403.
[32] Fix OK, Blumberg EA, Chang KM, et al.American Association for the Study of Liver Diseases Expert Panel Consensus Statement: Vaccines to Prevent Coronavirus Disease 2019 Infection in Patients With Liver Disease. Hepatology,2021, 74:1049-1064. |
